Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

Galderma

Status and phase: Completed; Phase 4

Conditions: Rosacea

Treatments: Drug: Metronidazole gel 1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00436527

US10041

Details and patient eligibility

About

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Full description

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.

Enrollment: 26 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions

Exclusion criteria

• Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

26 participants in 1 patient group

1

Other group

Treatment:

Drug: Metronidazole gel 1%